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Abstract 
Background: Platelets are components of blood involved in processes such as inflammation, metastasis and 
atherosclerosis by the use of adhesion molecules.sP-Selectin is a cellular adhesion molecule that promotes 
platelet-tumor cell interactions, venous thromboembolism and tumor metastasis. High plasma levels 
independently predict venous thrombosis in cancer patients and are known to play a major role in tumor 
metastasis. No study has determined the levels and associations of sP-selectin in prostate cancer patients in 
Africa.  
Objectives: To evaluate sP-selectin levels in prostate cancer patients and assess the associations with increased 
values. 
Methods: We prospectively enrolled 88 histologically diagnosed prostate cancer patients, reviewed their case 
notes for duration of presentingsymptoms, PSA at diagnosis, evidence of metastatic disease and history of co-
morbid states.  Also, 40 healthy male controls were enrolled. Full blood count was done using EDTA samples 
and citrated samples for sP-selectin determination using ELISA for both groups of subjects. 
Results: We found significantly reduced haemoglobin in cases than controls (10.79 ± 2.20 vs 13.59 ± 2.20g/dl; 
p= 0.001), sP-selectin was significantly higher in cases (57.86 ± 69.92vs 25.83 ± 9.72 ng/l; p =0.01).  Twenty 
four patients (27.3%) had sP-selectin levels >53.1ng/ml (mean 114.3 ± 171.1ng/mL). sP-selectin was 
significantly higher in patients whose BMI was > 25g/m
2
 (p=0.03), those with 2 or more co-morbidities 
(p=0.02) and more so in patients with diabetes mellitus (p=0.009). sP-selectin was increased in metastatic 
cancer patients, although not significantly.  
Conclusion: The findings from this study indicate that there is increased platelet activation in prostate cancer 
patients as measured by sP-selectin, indicating a significant cardiovascular risk in these patients. Platelet 
activation was significantly associated with higher BMI and presence of co-morbidities. The ability of sP-
selectin to predict metastasis and risk of VTE in this environment needs to be elucidated in studies with larger 
cohorts. 
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I. Introduction 
Platelet activation is associated with increased risk of venous thrombosis and patients with malignant 
conditions are at increased risk of thrombosis. P-selectin (CD62P) is an adhesion molecule stored within the a-
granules of platelets and the Weibel-Palade bodies of endothelial cells.,wWhen expressed on surfaces of cells, it 
is a marker of platelet activation.It is an endogenous lectin that can recognize sLe
x
-containing mucins,which  is 
used by the tumor cells to promote their progression to the metastatic phenotype.  Malignant cells are able to 
express on their surface the ligand CD24, which has been identified to be a receptor for this adhesion molecule. 
When P-selectin interacts with this ligand on malignant cells, it enables the activation of platelet and 
endothelium, thus supporting metastasis.  Platelet reactivity may mediate a final common pathway for venous 
thromboembolism in cancer patients. 
The relationship betweencancersand thrombosis was first described by Trousseauover a decade ago and 
many studies have reported this association over the years.In the developed world, Cancer patients account for 
about 20% of the burden of VTE patients andof every seven patients with cancer who die in hospital, one dies 
offrom pulmonary embolism.Although post-mortem studies revealed 50% incidence of thrombosis in cancer 
patients, generally, the risk factors for the development of VTE in cancer are varied and include:  the age of the 
patient, sex, site of cancer, duration of illness, presence of co-morbidities, treatment modalities and level of 
supportive care.  Prostate cancer is the leading cancer with significant morbidity in men of black African 
descent, the hospital incidence is 127/100,000 cases incidence in Nigeria and mortality as high as 64% has been 
reported within 2 years of diagnosis by one study.   
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Prostate cancer is generally not associated with a high risk for VTE, however it has been reported that VTE in 
prostate cancer patients is a predictor of reduced survival especially in those with advanced disease.The 
treatment modalities for prostate cancer such as androgen deprivation therapy and chemotherapy are also 
associated with increased risk of thrombosis.There is no documented study of  sP-selectin in prostate cancer 
patients in Africa that we are aware of, this study is aimed at determining the levels of sP-selectin in prostate 
cancer patients as compared with age-matched controls; as a way of evaluating platelet activation among 
prostate cancer patients. 
 
Patients and Methods 
The ethical committee of the University of Port Harcourt Teaching Hospital gave approval for this 
study.  We prospectively enrolled 88 men with histologically diagnosed prostate cancer that were willing to 
participate in the study.These patients were either yet to commence treatment or had initiated only one form of 
the modalities of treatment for prostate cancer at the Urology division of the surgery department.The few early 
cases had either radical prostatectomy or brachytherapy; the advanced cases had androgen deprivation therapy 
(orchidectomy orgoserelin).  Metastatic cases also had chemotherapy(docetaxel) and / or external beam 
radiotherapy. Castration resistant cases had low dose diethyl-stilbesterol, ketoconazole or abiraterone.   Patients 
were recruited from the clinics or the wards. Patients who declined or had a past history of thrombotic disorder 
or anticoagulation therapy were excluded.  Forty otherwise healthy male controls were also recruited.  The 
weight and height of all the subjects was measured and their BMIs were determined using standard calculations.  
The clinical notes of the patients were also reviewed and information about the age, educational status, 
presenting symptoms, duration of symptoms before presentation, history of other co-morbidities, ECOG 
performance status, history of hospitalization, alcohol and tobacco use, histologic diagnosis, Gleason’s score, 
PSA levels and treatment modality employed were documented on a proforma for each patient.   
Full blood counts using EDTA samples were  done within 30 minutes of sample collection using the 
KN1 3-part haemoanalyzer by Sysmex® and citrated samples were collected and centrifuged within 2 hours of 
collection at 2000g for 20 minutes at room temperature to produce platelet-poor plasma; they were then 
transferred and stored in aliquots in a plasma tube at -70
o
C till analyzed for sP-selectin determination using 
ELISA (R and D systems® UK). 
 
II. Results 
Between February2013 and October 2013, 88 eligible patients and 40 controls were enrolled.  The 
general characteristics of the patients in the study are in Table 1, the age range of the patients was from 41 to 85 
years, the peak prevalence of  prostate cancer was in the 60-69 age category, 44(50%). We found significantly 
reduced haemoglobin in cases than controls (10.79 ± 2.20 vs 13.59 ± 2.20g/dl; p= 0.001) and platelet count 
showed no significant difference(243.14 ± 150.85 vs 226.80 ± 53.83; p=0.503), however platelet count was 
significantly higher in hospitalized patients (p= 0.03) and those with metastatic disease (p<0.05), Table 2.  
SP-selectin was significantly higher in cases than controls (57.86 ± 69.92 vs 25.83 ± 9.72 ng/l; p 
=0.01), Figure 1.  No statistically significant difference was observed between sP-selectin levels in study 
participants who had metastatic disease and those that did not, Table 3.No significant correlation was found 
between sP-selectin level and platelet count (r = -0.03) Figure 2. 
Twenty four patients (27.3%) had sP-selectin levels >53.1ng/ml (mean 114.3 ± 171.1ng/mL). sP-
selectin was significantly higher in patients whose BMI was > 25kg/m
2
(p=0.03), those with 2 or more co-
morbidities (p=0.02) and more so in patients with diabetes mellitus (p=0.009).  
 
III. Discussion 
P-selectin is an adhesion molecule that is stored in the -granules of platelets and Weibel-Palade 
bodies of the endothelial cells, which when activated; play a role in inflammatory cell adhesion process.There is 
a strong relationship between cancer and the activation of the haemostatic system. Increased sP-selectin levelhas 
been studiedas an indicator of platelet activation, a facilitator of metastasis and a marker of increased 
cardiovascular risk in many patient groups.It has been studied in some cancer groups as a predictive marker of 
cancer-associated thrombosis, indicator of prognosis and in mice models as indicator for metastasis. A cut-off 
sP-selectin level of 53.1 ng/ml was taken to be a significant risk to predict the occurrence of VTE in cancer in a 
large prospective study by Ay et al. In our study, sP-selectin level higher than 53.1ng/ml in 27.3% of our 
patients indicating the risk for cardiovascular events in those patients. 
Many of the patients in the study population presented late (Table 1).This is a common finding reported 
by other researchers from this region and it is associated with advanced disease states at presentation
,
. 
Ignorance, poverty and poor health seeking behaviour are responsible for the late presentation. The diagnosis of 
metastatic prostatic cancer was largely based on clinical and radiological evaluation as documented by the 
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attending urologist in the patient’s clinical notes. Investigations for metastasis were individualized and included 
isotope bone scan, Magnetic resonance imaging, and lumbo-sacral spine x-rays.    
sP-selectin levels in this study were not related to the status of the tumors (metastasis, PSA or 
Gleason’s score).  The  increase in SP-selectin levels was however related tohigh BMIs and increased medical 
comorbidities in this group of patients.Increased platelet activation in prostate cancer may be due to metastasis, 
androgen deprivation therapy,  use of chemotherapeutic agents, stilbesterol and steroids. Some of our patients 
presented with paraplegia with attendant prolonged immobilization and increased risk of VTE. Most of the 
factors listed above are prevalent in our patients. 
Medical co-morbidities have a dramatic effect on the development of VTE in cancer patients and also 
their survival.Increased co-morbidity is associated with increased occurrence of VTE in ovarian cancer however 
this relationship is not very strong for breast cancer.  In Prostate cancer however, a cohort study of 44,035 
Danish prostate cancer patients showed that increased co-morbidity was associated with increased rates of VTE 
in the cohort. The authors noted that 40% of prostate cancer patients already had co-morbidities before the 
diagnosis of prostate cancer.The current treatment of prostate cancer by androgen deprivation therapy is also a 
major risk factor for the development of cardiovascular event .   The most common co-morbidities in our study 
are as documented in Table x.  Patients with diabetes mellitushad a significantly higher sP-selectin level 
(p=0.009) than those that did not have a diabetes.  It may be necessary to observe these patients more closely 
and offer thromboprophylaxis for those at significant risk such as surgery, prolonged immobilization or obesity; 
as this may potentially improve prognosis. 
In this study, patients who were overweight (BMI 25 – 29.99) had mean sP-selectin levels of 63.88 ± 
82.52ng/mL, while those who were obese (BMI > 30) had a mean sP-selectin of 138.33 ± 117.25. Clinical and 
epidemiological data support the relationship between obesity and thrombosis, and in the circumstance ofcancer 
the relationship may be stronger.  
This study has some limitation as it is cross-sectional;it cannot directly imply a cause and effect inter-
relationship between platelet activation ormetastasis and formation of thrombosis in this group of patients.  The 
small sample size may also be contributory.   
 
IV. Conclusion 
Platelet activation is increased in prostate cancer patients in Africa just as shown in other parts of the 
world. Additionally, the study shows an association of increase sP-selectin with high BMI and medical co-
morbidity, especially diabetes mellitus.  Larger observational studies may be helpful to identify patients with 
high sP-selectin that develop thrombosis and as this information may be useful in planning for 
thromboprophylaxis for patients with similar clinical presentation. 
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